IDH1 and glioblastoma: MGMT promoter region was recognized to have a predictive value for the efficacy of TMZ-based chemotherapy, and mutations in the genes encoding for iso-citrate dehydrogenases 1/2 (IDH1/2) could predict a relatively long-term survival of GBM patients (Feyissa et al., 2019; Radke et al., 2019).